53.03
+0.22(+0.42%)
Currency In USD
| Previous Close | 52.81 |
| Open | 52.66 |
| Day High | 53.19 |
| Day Low | 52.13 |
| 52-Week High | 103.81 |
| 52-Week Low | 47.04 |
| Volume | 868,418 |
| Average Volume | 996,727 |
| Market Cap | 2.91B |
| PE | -30.3 |
| EPS | -1.75 |
| Moving Average 50 Days | 60.19 |
| Moving Average 200 Days | 73.7 |
| Change | 0.22 |
If you invested $1000 in PROCEPT BioRobotics Corporation (PRCT) since IPO date, it would be worth $1,264.43 as of April 20, 2025 at a share price of $53.03. Whereas If you bought $1000 worth of PROCEPT BioRobotics Corporation (PRCT) shares 3 years ago, it would be worth $1,375.97 as of April 20, 2025 at a share price of $53.03.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas
GlobeNewswire Inc.
Apr 10, 2025 8:03 PM GMT
SAN JOSE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company, whose mission is to revolutionize BPH treatment globally, announced today it will host an in-person in
WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation
GlobeNewswire Inc.
Mar 24, 2025 12:00 PM GMT
Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a randomized, multicenter trialSAN JOSE, Calif., March 24,
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada
GlobeNewswire Inc.
Mar 14, 2025 12:00 PM GMT
SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it
Data not available